

## Cyclosporine Formulation

Version 4.0      Revision Date: 2024/07/06      SDS Number: 608880-00021      Date of last issue: 2024/05/16  
Date of first issue: 2016/04/08

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Cyclosporine Formulation  
Other means of identification : Optimmune (A007869)  
OPTIMMUNE OPHTHALMIC OINTMENT (51551)

#### Manufacturer or supplier's details

Company : MSD  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : +1-908-740-4000  
Emergency telephone number : +1-908-423-6000  
E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product  
Restrictions on use : Not applicable

---

### 2. HAZARDS IDENTIFICATION

#### GHS Classification

Carcinogenicity : Category 1B

#### GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H350 May cause cancer.

Precautionary statements :

#### Prevention:

P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

#### Response:

## Cyclosporine Formulation

Version 4.0      Revision Date: 2024/07/06      SDS Number: 608880-00021      Date of last issue: 2024/05/16  
Date of first issue: 2016/04/08

---

P308 + P313 IF exposed or concerned: Get medical advice/attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

---

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Petrolatum	8009-03-8	>= 30 -< 60
Cyclosporine	59865-13-3	>= 0.1 -< 0.3

---

**4. FIRST AID MEASURES**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause cancer.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.
- 

**5. FIREFIGHTING MEASURES**

## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/05/16
4.0	2024/07/06	608880-00021	Date of first issue: 2016/04/08

---

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.
- 

### 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
- 

### 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
-

## Cyclosporine Formulation

Version 4.0      Revision Date: 2024/07/06      SDS Number: 608880-00021      Date of last issue: 2024/05/16  
 Date of first issue: 2016/04/08

- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
 Do not breathe vapours or spray mist.  
 Do not swallow.  
 Avoid contact with eyes.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Keep container tightly closed.  
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.  
 Store locked up.  
 Keep tightly closed.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Petrolatum	8009-03-8	NAB (Mist)	5 mg/m <sup>3</sup>	ID OEL
		PSD (Mist)	10 mg/m <sup>3</sup>	ID OEL
		TWA (Inhalable particulate matter)	5 mg/m <sup>3</sup>	ACGIH
Cyclosporine	59865-13-3	TWA	10 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

- Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

**Personal protective equipment**

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Combined particulates and organic vapour type

## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/05/16
4.0	2024/07/06	608880-00021	Date of first issue: 2016/04/08

---

## Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

**9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance	: ointment
Colour	: colourless, to, light yellow
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available

**Cyclosporine Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/05/16
4.0	2024/07/06	608880-00021	Date of first issue: 2016/04/08

---

Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics	:	
Particle size	:	Not applicable

---

**10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

**Cyclosporine Formulation**

Version 4.0      Revision Date: 2024/07/06      SDS Number: 608880-00021      Date of last issue: 2024/05/16  
Date of first issue: 2016/04/08

---

**Acute toxicity**

Not classified based on available information.

**Components:****Petrolatum:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Method: OECD Test Guideline 401  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity  
Remarks: Based on data from similar materials

**Cyclosporine:**

Acute oral toxicity : LD50 (Rat): 1,480 mg/kg  
LD50 (Mouse): 2,329 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Mouse): 107 mg/kg  
Application Route: Intravenous  
LD50 (Rat): 25.8 mg/kg  
Application Route: Intravenous

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Petrolatum:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Cyclosporine:**

Remarks : No data available  
May irritate skin.

**Serious eye damage/eye irritation**

Not classified based on available information.

## Cyclosporine Formulation

Version 4.0      Revision Date: 2024/07/06      SDS Number: 608880-00021      Date of last issue: 2024/05/16  
Date of first issue: 2016/04/08

---

### Components:

#### **Petrolatum:**

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405  
Remarks : Based on data from similar materials

#### **Cyclosporine:**

Remarks : No data available  
May irritate eyes.

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

### Components:

#### **Petrolatum:**

Test Type : Buehler Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : negative  
Remarks : Based on data from similar materials

#### **Cyclosporine:**

Remarks : May cause sensitisation of susceptible persons.

### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Petrolatum:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Result: negative  
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Method: OECD Test Guideline 474  
Result: negative  
Remarks: Based on data from similar materials

## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/05/16
4.0	2024/07/06	608880-00021	Date of first issue: 2016/04/08

---

**Cyclosporine:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Test system: Chinese hamster cells Result: negative
		Test Type: sister chromatid exchange assay Result: positive
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
		Test Type: Chromosomal aberration Species: Chinese hamster Cell type: Bone marrow Result: negative
		Test Type: Chromosomal aberration Species: Mouse Result: negative

**Carcinogenicity**

May cause cancer.

**Components:****Petrolatum:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	2 Years
Result	:	negative

**Cyclosporine:**

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	78 weeks
LOAEL	:	4 mg/kg body weight
Result	:	positive
Target Organs	:	Liver, lymphatic system

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
LOAEL	:	0.5 mg/kg body weight
Result	:	positive
Target Organs	:	Pancreas

## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/05/16
4.0	2024/07/06	608880-00021	Date of first issue: 2016/04/08

---

Species	: Humans
Result	: May cause cancer.
Target Organs	: Immune system, Skin
Remarks	: Information taken from reference works and the literature.

Carcinogenicity - Assessment	: May cause cancer.
------------------------------	---------------------

**Reproductive toxicity**

Not classified based on available information.

**Components:****Petrolatum:**

Effects on fertility	: Test Type: Reproduction/Developmental toxicity screening test Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials
----------------------	--

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Skin contact Result: negative Remarks: Based on data from similar materials
-------------------------------	--

**Cyclosporine:**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity F1: LOAEL: 15 mg/kg body weight Result: No effects on fertility, Effect on reproduction capacity
----------------------	--

Test Type: Fertility
Species: Rat, males
Application Route: Subcutaneous
Fertility: LOAEL: 10 mg/kg body weight
Result: Reduced fertility

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 30 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced foetal weight, foetal mortality, Retardations, Teratogenic effects
-------------------------------	--

Test Type: Embryo-foetal development
Species: Rabbit
Developmental Toxicity: LOAEL: 100 mg/kg body weight

## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/05/16
4.0	2024/07/06	608880-00021	Date of first issue: 2016/04/08

---

Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced foetal weight, foetal mortality, Retardations, Teratogenic effects

Test Type: Development  
 Species: Rabbit  
 Application Route: Subcutaneous  
 Developmental Toxicity: LOAEL: 10 mg/kg body weight  
 Target Organs: Kidney  
 Result: Visceral malformations

Test Type: Development  
 Species: Rat  
 Application Route: Intravenous  
 Developmental Toxicity: LOAEL: 12 mg/kg body weight  
 Target Organs: Heart  
 Result: Visceral malformations

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

**Components:****Cyclosporine:**

Target Organs	:	Kidney, Liver, Immune system
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Petrolatum:**

Species	:	Rat
NOAEL	:	5,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	2 yr

**Cyclosporine:**

Species	:	Rat
NOAEL	:	14 mg/kg
LOAEL	:	45 mg/kg
Application Route	:	Oral
Exposure time	:	90 Days
Target Organs	:	Kidney, Liver, Immune system
Symptoms	:	hair loss

## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/05/16
4.0	2024/07/06	608880-00021	Date of first issue: 2016/04/08

---

Species	: Monkey
NOAEL	: 20 mg/kg
LOAEL	: 60 mg/kg
Application Route	: Oral
Exposure time	: 90 Days
Target Organs	: Immune system
Symptoms	: Gastrointestinal disturbance, Liver disorders, Kidney disorders

Species	: Dog
LOAEL	: 15 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Immune system
Symptoms	: Changes in the blood count, Kidney disorders, Skin disorders, hair loss

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Cyclosporine:**

Inhalation	: Remarks: May cause irritation of respiratory tract.
Skin contact	: Remarks: May irritate skin.
Eye contact	: Symptoms: Eye irritation, eye pain
Ingestion	: Symptoms: Kidney disorders, Tremors, hypertension, blood effects, Gastrointestinal disturbance

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Petrolatum:**

Toxicity to fish	: LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 10,000 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	: NOEL (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction

## Cyclosporine Formulation

Version 4.0      Revision Date: 2024/07/06      SDS Number: 608880-00021      Date of last issue: 2024/05/16  
Date of first issue: 2016/04/08

---

Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 10 mg/l  
Exposure time: 21 d  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Petrolatum:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 31 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301F  
Remarks: Based on data from similar materials

**Bioaccumulative potential**

No data available

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Environmentally hazardous : no

**IATA-DGR**

## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/05/16
4.0	2024/07/06	608880-00021	Date of first issue: 2016/04/08

---

UN/ID No. : Not applicable  
 Proper shipping name : Not applicable  
 Class : Not applicable  
 Subsidiary risk : Not applicable  
 Packing group : Not applicable  
 Labels : Not applicable  
 Packing instruction (cargo aircraft) : Not applicable  
 Packing instruction (passenger aircraft) : Not applicable

**IMDG-Code**

UN number : Not applicable  
 Proper shipping name : Not applicable  
 Class : Not applicable  
 Subsidiary risk : Not applicable  
 Packing group : Not applicable  
 Labels : Not applicable  
 EmS Code : Not applicable  
 Marine pollutant : Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Special precautions for user**

Not applicable

**15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

**Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.**

**Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health**

Hazardous substances that must be registered : Not applicable

**Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances**

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

**Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials**

Type of hazardous materials subject to distribution and control, Annex I : Not applicable

## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/05/16
4.0	2024/07/06	608880-00021	Date of first issue: 2016/04/08

---

Type of hazardous materials subject to distribution and control, Annex II : Not applicable

**The components of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

---

### 16. OTHER INFORMATION

Revision Date : 2024/07/06

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

**Full text of other abbreviations**

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
ID OEL	:	Indonesia. Occupational Exposure Limits

ACGIH / TWA	:	8-hour, time-weighted average
ID OEL / NAB	:	Long term exposure limit
ID OEL / PSD	:	Short term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect

## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/05/16
4.0	2024/07/06	608880-00021	Date of first issue: 2016/04/08

---

Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN